Trial reportScientific reports2021
Identification of an optimal prolactin threshold to determine prolactinoma size using receiver operating characteristic analysis.
Trial report in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- Disentangling secretory ambiguity and the limitations of classical thresholds in defining prolactinomas.Pituitary · 2026Article
- Prolactinomas in women of reproductive age: a proposed reproductive-intent-based framework for diagnosis and management.Frontiers in endocrinology · 2026Review
- Aggressive prolactinomas in men are associated with visual disturbances and pituitary hormone deficiencies.Scientific reports · 2025Article
- Recovery of hypopituitarism in macroprolactinomas: a comparison of medical vs. surgical treatment. Results from a European multicenter study.Journal of endocrinological investigation · 2025Article
- The Influence of Pituitary Morphology on the Occurrence of Hormonal Disorders in Patients with Empty Sella or Partial Empty Sella.Biomedicines · 2025Article
- Gender differences in prolactin thresholds and their association with lactotroph adenoma invasiveness for potential treatment considerations.Scientific reports · 2025Article
- Relationship Between Radiological Features of Primary Empty or Primary Partial Empty Sella and Pituitary Hormone Levels.Biomedicines · 2025Article
- Breast Cancer risk in patients with dopamine agonist-treated hyperprolactinemia.Journal of endocrinological investigation · 2025Article
- Prolactinoma: Navigating the Dual Challenge of Side Effects and Treatment Strategies - A Comprehensive Review.Annals of medicine and surgery (2012) · 2024Review
- Gender-specific prolactin thresholds to determine prolactinoma size: a novel Bayesian approach and its clinical utility.Frontiers in surgery · 2024Article
- Cabergoline Failure and a Spontaneous Pregnancy in a Microprolactinoma with High Prolactin Levels.Journal of personalized medicine · 2022Article
- Resolution of Visual Field Defect in Macroprolactinoma After Treatment With Cabergoline.Cureus · 2022Article
- Diagnostic criteria of small sellar lesions with hyperprolactinemia: Prolactinoma or else.Frontiers in endocrinology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prolactinomas represent the most common type of secretory pituitary neoplasms, with a therapeutic management that varies considerably based on tumour size and degree of hyperprolactinemia. The aim of the current study was to evaluate the relationship between serum prolactin (PRL) concentrations and prolactinoma size, and to determine a cut-off PRL value that could differentiate micro- from macro-prolactinomas. A retrospective cohort study of 114 patients diagnosed with prolactinomas between 2007 and 2017 was conducted. All patients underwent gadolinium enhanced pituitary MRI and receiver operating characteristic (ROC) analyses were performed. 51.8% of patients in this study were men, with a mean age at the time of diagnosis of 42.32 ± 15.04 years. 48.2% of the total cohort were found to have microadenomas. Baseline serum PRL concentrations were strongly correlated to tumour dimension (r = 0.750, p = 0.001). When performing the ROC curve analysis, the area under the curve was 0.976, indicating an excellent accuracy of the diagnostic method. For a value of 204 μg/L (4338 mU/L), sensitivity and specificity were calculated at 0.932 and 0.891, respectively. When a cut off value of 204 μg/L (4338 mU/L) was used, specificity was 93.2%, and sensitivity 89.1%, acceptable to reliably differentiate between micro- and macro- adenomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.